Efkarpia

• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) Ended
  2022-502837-24-00 5 2023-09-25 Overweight
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa
• A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of c … Ended
  2024-518430-91-00 5 2023-06-13 Acne Vulgaris
• A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. Ended
  2023-509746-35-00 4 2023-05-16 Primary Discoid Lupus Erythematosus
• A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin for the … Ended
  2024-516385-10-00 4 2023-05-02 Acute Bacterial Skin and Skin Structure Infections
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25 Atopic Dermatitis
• Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of r … Ended
  2024-514677-22-00 5 2023-03-23 Restoration of sinus rhythm in patients with recent AF onset
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight … Ended
  2023-509668-11-00 6 2022-06-15 Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
• A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended
  2023-508645-40-00 10 2022-05-10 Bullous Pemphigoid (BP)
• The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended
  2024-510872-18-00 4 2022-05-09 Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (
• An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult … Ended
  2024-515832-59-00 5 2022-05-03 Bullous Pemphigoid
• A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease Ended
  2023-506897-11-00 5 2021-10-18 Non-diabetic chronic kidney disease
• An extension study to learn if Bimekizumab is safe and works as a long-term therapy in adults with moderate to severe hidradenitis suppurati … Ended
  2024-511035-10-00 5 2021-06-23 Hidradenitis Suppurativa
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• Extension study to evaluate the long-term outcomes of subjects in study 20090 Ended
  2023-504207-89-00 5 2020-03-27 Retinopathy of prematurity
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Ended
  2024-515052-20-00 5 2017-09-20 Non-small Cell Lung Cancer
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca

Showing 97–118 of 118 trials